Dr. Ponlawat Maki holds a doctorate in Applied Thai Traditional Medicine. He specializes in integrating traditional medical practices with modern healthcare, promoting holistic wellness, and developing herbal formulas for contemporary medical use.

Apiwat Piriyapol is a research associate at Medical Innovation Development and Assessment Support (MIDAS). His training was in labour economics with experience in urban health economics. His current interest is in conducting medical technology assessment to promote advanced technology to the healthcare system.

Benjarin Santatiwongchai is Head of Communication for HITAP. Having studied BSc in Pharmacy from Mahidol University, her knowledge in current and emerging medical technologies and interventions has led her to become involved with Health Technology Assessment. In 2012, she completed her MSc in Health Economics at the University of York. She is now a

This report aims to describe the study visit of researchers at Christian Medical College (CMC) Vellore who are undertaking cost of illness studies on enteric fever and rotavirus vaccines in India at the Health Intervention and Technology Assessment Program (HITAP). HITAP, known regionally for suppor

The Health Intervention and Technology Assessment Program (HITAP) has supported the development of Health Technology Assessment (HTA) in India by building technical capacity and knowledge through collaborations with several academic institutions in India on HTA. HITAP recently partnered with the Jaw

INTRODUCTION TO THE YEAR’S EVENTS 2015 was our best year yet – a year that saw our international Decision Support Initiative (iDSI) grow from a fledgling enterprise to a trusted source of knowledge and support for those setting healthcare priorities. With our iDSI partners in Thailand (HITAP),

Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment Sitaporn Youngkong*1,2, Rob Baltussen*1, Sripen Tantivess*2, Xander Koolman*3 and Yot Teerawattananon*2 1 Nijmegen International Center for Health Systems Research and Education (NICHE), Department of

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I